In subjects with PAH, transition from Tyvaso^® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes

Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events

FDA action on the New Drug Application for Tyvaso DPI is expected by May 2022

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–April 6, 2022–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation. ...  Read more

The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom. ...  Read more

Pilot program created to enable promising, diverse, and underrepresented women business leaders a more equitable future ...  Read more

Maryland tech start-up developed a platform that manages wellness data for employers and families ...  Read more

Monday, April 4, 2022 – Three portfolio companies have graduated from the Germantown Innovation Center (GIC), Montgomery County’s business incubator program. The County’s incubator program started in 1999 to foster the growth and development of young technology companies. Akan Biosciences, Intelligent Fusion Technology and Seraxis are the three County-based companies graduating from the program this spring. ...  Read more

Innovative social wellness platform Givhero has just received new investment from partners including TEDCO, the University of MD Momentum Fund and others. See how helping employees care about wellness increases productivity and reduces company costs for tech company Givhero. ...  Read more

Global Alliant is excited to announce that we have made the 2022 #IncRegionals Mid-Atlantic list. We have been ranked No. 6 on this prestigious listing of fastest-growing private companies.  ...  Read more

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor. The round was initiated in May 2021 and led by Deerfield Management Company, with participation from a second institutional investor and Mayo Clinic. Proceeds of the AMR Action Fund’s investment are primarily intended to support APT’s clinical trials to address substantial unmet patient needs in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO).  ...  Read more

S.H.E. Pitch , now in its second year, is a pitch competition for female CEOs – or “S.H.E.-EOs” – designed to give businesses both in the “idea stage” and “growth stage” cash prizes, publicity and networking opportunities. ...  Read more